Topic: restructuring

LivaNova plans to restructure its heart valve operations, and will drop its investigational Caisson transcatheter mitral valve replacement altogether.

In a bid to streamline the review of new treatments for cancer, the FDA has reorganized and renamed the Office of Hematology and Oncology Products.

With the failure of its lead program in pancreatic cancer, Halozyme is cutting drug development to focus solely on its drug delivery technology.

As each company works to cut costs and stay alive, Acorda will lay off about one-quarter of its employees, while Alkermes will cut 160 jobs.

The cuts will leave Five Prime with a “small research group” focused on taking clinical candidates forward with the help of service providers.

The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B.

Compugen is “streamlining” its R&D operations to pare down costs and ensure it can afford the phase 1 study of its lead asset, an anti-PVRIG antibody.

The major restructuring is intended to keep Merrimack operating and raking in milestones from Ipsen while it looks into strategic alternatives.

The latest restructuring is intended to slash up to 40% of Achaogen’s expenses, enabling the antibiotic company to hunker down and search for an exit.

Bayer is contemplating outsourcing more of its R&D as part of an overall restructuring plan, Reuters says.